WILLIAM T. FRIEDEWALD, M.D.; MAX HALPERIN, PH.D.
This content is PDF only. Please click on the PDF icon to access.
The efficacy of clofibrate treatment for primary and secondary prevention of ischemic heart disease has been a topic of keen interest for some time, mainly because of the lipid-lowering properties of this drug, and its relatively low incidence of adverse effects. A recent issue of the British Medical Journal contains reports from two completed secondary-prevention trials of clofibrate, one by a group of physicians in the Newcastle-upon-Tyne region (1, 2) and one by a research committee of the Scottish Society of Physicians (2, 3). These trials were separate, cooperative ventures and used a randomized, double-blind design, except for a subsegment
FRIEDEWALD WT, HALPERIN M. Clofibrate in Ischemic Heart Disease. Ann Intern Med. ;76:821–823. doi: 10.7326/0003-4819-76-5-821
Download citation file:
Published: Ann Intern Med. 1972;76(5):821-823.
Cardiology, Coronary Heart Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use